OBJECTIVES: The objective of this study is to investigate preoperative hematological parameters for anemia, leukocytosis and thrombocytosis in relation to established prognostic factors and survival in endometrial cancer. METHODS: 557 patients treated for endometrial carcinoma were prospectively included in a study focusing on the relationship between preoperative hemoglobin, leukocyte and platelet counts, and a panel of clinicopathological characteristics and outcome. RESULTS: Preoperative anemia was present in 15.8%, leukocytosis in 11.2% and thrombocytosis in 12.1%. Among patients with localized disease (FIGO stage I/II), 18.1% had anemia and/or thrombocytosis at diagnosis. Patients with advanced disease (high FIGO stage and lymph-node metastasis) had significantly lower hemoglobin count, higher leukocyte count and higher platelet count (all p<0.008). Patients with anemia, leukocytosis and thrombocytosis had significantly shorter 5-year disease-specific survival of 61.3%, 66.0% and 61.0% respectively, compared to 87.7%, 86.3% and 87.3% for patients with normal counts (all p<0.001). In multivariate Cox regression analysis, lower hemoglobin counts and higher platelet counts were independently associated with poor outcome adjusted for the standardly applied prognostic markers (p<0.033). CONCLUSION: Preoperative anemia, leukocytosis or thrombocytosis in women with endometrial carcinoma is associated with advanced disease and poor disease-specific survival.
OBJECTIVES: The objective of this study is to investigate preoperative hematological parameters for anemia, leukocytosis and thrombocytosis in relation to established prognostic factors and survival in endometrial cancer. METHODS: 557 patients treated for endometrial carcinoma were prospectively included in a study focusing on the relationship between preoperative hemoglobin, leukocyte and platelet counts, and a panel of clinicopathological characteristics and outcome. RESULTS: Preoperative anemia was present in 15.8%, leukocytosis in 11.2% and thrombocytosis in 12.1%. Among patients with localized disease (FIGO stage I/II), 18.1% had anemia and/or thrombocytosis at diagnosis. Patients with advanced disease (high FIGO stage and lymph-node metastasis) had significantly lower hemoglobin count, higher leukocyte count and higher platelet count (all p<0.008). Patients with anemia, leukocytosis and thrombocytosis had significantly shorter 5-year disease-specific survival of 61.3%, 66.0% and 61.0% respectively, compared to 87.7%, 86.3% and 87.3% for patients with normal counts (all p<0.001). In multivariate Cox regression analysis, lower hemoglobin counts and higher platelet counts were independently associated with poor outcome adjusted for the standardly applied prognostic markers (p<0.033). CONCLUSION: Preoperative anemia, leukocytosis or thrombocytosis in women with endometrial carcinoma is associated with advanced disease and poor disease-specific survival.
Authors: Tina Schubert; Tilman Todenhöfer; Johannes Mischinger; Christian Schwentner; Markus Renninger; Arnulf Stenzl; Georgios Gakis Journal: World J Urol Date: 2015-09-29 Impact factor: 4.226
Authors: Aaron Denson; Nancy Burke; Georgine Wapinsky; Barbara Bertels; Tzu-Hua Juan; Jae Lee; Gregory M Springett; Jonathan R Strosberg; Richard D Kim; Dan M Sullivan; Amit Mahipal Journal: Am J Clin Oncol Date: 2018-02 Impact factor: 2.339
Authors: Sigmund Ytre-Hauge; Jenny A Husby; Inger J Magnussen; Henrica M J Werner; Øyvind O Salvesen; Line Bjørge; Jone Trovik; Ingunn M Stefansson; Helga B Salvesen; Ingfrid S Haldorsen Journal: Int J Gynecol Cancer Date: 2015-03 Impact factor: 3.437